Evidence map›Paper›PMID 26022204›Full record

ArticleJournal of hematology & oncology2015

HER2/neu-directed therapy for biliary tract cancer.

Milind Javle, Chaitanya Churi, HyunSeon C Kang, Rachna Shroff, Filip Janku, Rakesh Surapaneni, Mingxin Zuo, Christian Barrera, Humaid Alshamsi, Sunil Krishnan and 5 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hematology & oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05718115 (Deep Learning Radiogenomics For Individualized Therapy in Unresectable Gallbladder Cancer), which is not on this map. Cited by 115 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed, 3 pooled it
13.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05718115 unknown statusnot on this mapstarted 2023, after this paper: background citation

Deep Learning Radiogenomics For Individualized Therapy in Unresectable Gallbladder Cancer

TypeobservationalSponsorPost Graduate Institute of Medical Education and Research, ChandigarhRan2023 to 2023Enrolled75ConditionsGallbladder CancerArmsCT scan
3 · Its place in the literature

Who cites it

115 citing papers in PubMed, 3 syntheses or guidelines pooled it, 221 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  17. Review
  18. Review
  19. Article
  20. Article

55 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Milind JavleDepartment of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit Number 426, Room Number FC10.3062, Houston, TX, 77030, USA. mjavle@mdanderson.org.
Chaitanya ChuriDepartment of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit Number 426, Room Number FC10.3062, Houston, TX, 77030, USA.
HyunSeon C KangDepartment of Diagnostic Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rachna ShroffDepartment of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit Number 426, Room Number FC10.3062, Houston, TX, 77030, USA.
Filip JankuDepartment of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rakesh SurapaneniScott & White Clinic, Temple, TX, USA.
Mingxin ZuoDepartment of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit Number 426, Room Number FC10.3062, Houston, TX, 77030, USA.
Christian BarreraDepartment of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit Number 426, Room Number FC10.3062, Houston, TX, 77030, USA.
Humaid AlshamsiDepartment of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit Number 426, Room Number FC10.3062, Houston, TX, 77030, USA.
Sunil KrishnanDepartment of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lopa MishraDepartment of Gastroenterology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Robert A WolffDepartment of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit Number 426, Room Number FC10.3062, Houston, TX, 77030, USA.
Ahmed O KasebDepartment of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit Number 426, Room Number FC10.3062, Houston, TX, 77030, USA.
Melanie B ThomasGibbs Cancer Center & Research Institute, Spartanburg, SC, USA.
Abby B SiegelDepartments of Medicine and Surgery, Columbia University, 622 West 168th Street, PH-14, room 105 C, New York, NY, 10032, USA. aas54@cumc.columbia.edu.
The University of Texas MD Anderson Cancer Center · USColumbia University · US

Funding

Targeting CDK4 in TGS-B Inactivated Gastrointestinal CancersP01CA130821 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MISHRA, LOPA · 2008 to 2013
$6.9M
Role of Beta Spectrin and Smad in Alcohol-Induced Liver and GI Cell ProliferationR01AA023146 · NIAAA · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Lopa Mishra · 2013 to 2026
$4.6M
NCI NIH HHS P01 CA130821NIAAA NIH HHS R01 AA023146
6 · The paper itself

Abstract

backgroundBiliary cancers are highly aggressive tumors that are often diagnosed an advanced disease stage and have a poor outcome with systemic therapy. Recent efforts towards molecular characterization have identified a subset of biliary patients that have HER2/neu amplification or mutation. HER2/neu amplification is associated with response to HER2/neu-directed therapy in breast and gastric cancers. However, the efficacy of HER2/neu-targeted therapy in biliary cancers is unknown. PATIENTS AND

methodsWe retrospectively reviewed cases of advanced gallbladder cancer and cholangiocarcinoma with HER2/neu genetic aberrations or protein overexpression who received HER2/neu-directed therapy between 2007 and 2014. Clinical data were retrieved from medical records, and imaging studies were independently reviewed.

resultsNine patients with gallbladder cancer and five patients with cholangiocarcinoma had received HER2/neu-directed therapy (trastuzumab, lapatinib, or pertuzumab) during the study period. In the gallbladder cancer group, HER2/neu gene amplification or overexpression was detected in eight cases. These patients experienced disease stability (n = 3), partial response (n = 4), or complete response (n = 1) with HER2/neu-directed therapy. One patient had HER2/neu mutation and experienced a mixed response after lapatinib therapy. The duration of response varied from 8+ to 168 weeks (median 40 weeks), and three patients are still on therapy. One patient developed HER2/neu amplification as a secondary event after FGFR-directed therapy for FGF3-TACC3 gene fusion. The cholangiocarcinoma cases treated in this series had a higher proportion of HER2/neu mutations, and no radiological responses were seen in these patients despite HER2/neu-directed therapy.

conclusionsHER2/neu blockade is a promising treatment strategy for gallbladder cancer patients with gene amplification and deserves further exploration in a multi-center study.

Indexed as

AdultBiliary Tract NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleGallbladder NeoplasmsHumansImmunohistochemistryMaleMiddle AgedRetrospective StudiesYoung AdultERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases

Identifiers

PMID26022204
PMCPMC4469402
OpenAlexW1891752511

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.